Last reviewed · How we verify
Phase 2; Low Dose MYOBLOC
At a glance
| Generic name | Phase 2; Low Dose MYOBLOC |
|---|---|
| Also known as | rimabotulinumtoxinB, botulinum toxin type B |
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity (PHASE2, PHASE3)
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phase 2; Low Dose MYOBLOC CI brief — competitive landscape report
- Phase 2; Low Dose MYOBLOC updates RSS · CI watch RSS
- Supernus Pharmaceuticals, Inc. portfolio CI